The role of HER2 in cancer therapy and targeted drug delivery.
HER2 is highly expressed in a significant proportion of breast cancer, ovarian cancer, and gastric cancer. Since the discovery of its role in tumorigenesis, HER2 has received great attention in cancer research during the past two decades. Successful development of the humanized monoclonal anti-HER2 antibody (Trastuzumab) for the treatment of breast cancer further spurred scientists to develop various HER2 specific antibodies, dimerization inhibitors and kinase inhibitors for cancer therapy. On the other hand, the high expression of HER2 and the accessibility of its extracellular domain make HER2 an ideal target for the targeted delivery of anti-tumor drugs as well as imaging agents. Although there is no natural ligand for HER2, artificial ligands targeting HER2 have been developed and applied in various targeted drug delivery systems. The emphasis of this review is to elucidate the roles of HER2 in cancer therapy and targeted drug delivery. The structure and signal pathway of HER2 will be briefly described. The role of HER2 in tumorigenesis and its relationship with other tumor markers will be discussed. For the HER2 targeted cancer therapy, numerous strategies including the blockage of receptor dimerization, inhibition of the tyrosine kinase activity, and interruption of the downstream signal pathway will be summarized. For the targeted drug delivery to HER2 positive tumor cells, various targeting ligands and their delivery systems will be described in details.
Tai
Wanyi
W
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA.
Mahato
Rubi
R
Cheng
Kun
K
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000378:metabolism*
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases
Ann Oncol. 2001;12 Suppl 1:S9-13
11521729
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
16829981
J Biol Chem. 2007 Apr 6;282(14):10432-40
17283074
Cancer Res. 2007 Mar 1;67(5):2178-86
17332348
Mol Pharm. 2006 Nov-Dec;3(6):726-36
17140260
Cancer Cell. 2004 Nov;6(5):427-8
15542423
Breast Cancer Res Treat. 2006 Aug;98(3):295-301
16752078
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15937-40
12461170
Cancer Cell. 2004 Sep;6(3):251-61
15380516
Cancer Immunol Immunother. 2007 Sep;56(9):1507-12
17310381
Mol Cell Biol. 1988 Apr;8(4):1831-4
3260004
Nat Med. 2000 Apr;6(4):443-6
10742152
Science. 1987 Jul 10;237(4811):178-82
2885917
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
Breast Cancer Res Treat. 2001 Mar;66(2):159-64
11437102
Cancer Res. 2007 Mar 15;67(6):2773-82
17363599
Mol Syst Biol. 2005;1:2005.0008
16729043
J Biol Chem. 1997 Nov 21;272(47):29482-6
9368008
Physiol Rev. 1999 Jul;79(3):703-61
10390517
Cancer Res. 2006 Apr 1;66(7):3764-72
16585203
Int J Cancer. 2004 Mar 1;108(6):922-9
14712498
Cancer Res. 2004 Feb 15;64(4):1460-7
14973048
Oncol Rep. 2002 Sep-Oct;9(5):915-28
12168049
Oncogene. 2007 May 28;26(25):3637-43
17530017
Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37
12138395
Mol Cancer Res. 2008 Mar;6(3):446-57
18337451
Cancer Cell. 2002 Mar;1(2):117-23
12086869
Nat Clin Pract Oncol. 2006 May;3(5):269-80
16683005
J Natl Cancer Inst. 1993 Aug 4;85(15):1230-5
8101229
Biochem J. 1998 Aug 1;333 ( Pt 3):757-63
9677338
Br J Cancer. 2007 Feb 12;96(3):485-91
17245339
Int J Cancer. 2004 Jan 1;108(1):71-7
14618618
Clin Cancer Res. 2002 Apr;8(4):1172-81
11948130
Mol Pharm. 2009 May-Jun;6(3):649-50
19485323
Int J Biol Markers. 2003 Apr-Jun;18(2):152-5
12841685
J Biol Chem. 2002 Jun 21;277(25):22692-8
11950845
J Biol Chem. 2004 May 14;279(20):21343-8
15004021
J Virol. 2008 Jan;82(2):630-7
17989185
Cancer Res. 2001 Oct 1;61(19):7196-203
11585755
Nature. 2006 Jan 12;439(7073):168-74
16273093
Cancer Cell. 2004 Nov;6(5):517-27
15542435
DNA Cell Biol. 2005 Jun;24(6):350-8
15941387
Oncogene. 1994 Jul;9(7):1829-38
7911565
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Cancer Res. 2004 Sep 15;64(18):6652-9
15374980
Mol Endocrinol. 2004 Jun;18(6):1396-410
15056731
Handb Exp Pharmacol. 2008;(185 Pt 2):145-63
18626602
Breast Cancer. 2008;15(1):65-72
18224397
Cancer Cell. 2004 Nov;6(5):459-69
15542430
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
12516034
Clin Cancer Res. 2008 Jun 15;14(12):3840-9
18559604
Breast Cancer Res. 2006;8(1):R4
16417653
Gene Ther. 2006 Apr;13(7):646-51
16341056
Drugs. 2007;67(9):1329-41
17547474
Cancer Res. 2001 Mar 15;61(6):2420-3
11289108
Angiogenesis. 2004;7(1):59-68
15302997
J Biol Chem. 2004 Feb 6;279(6):4339-45
14625284
BioDrugs. 2007;21(2):69-77
17402790
Nat Clin Pract Oncol. 2008 Sep;5(9):512-20
18594499
J Clin Oncol. 2005 Apr 10;23(11):2534-43
15699478
Cancer Res. 2008 Nov 15;68(22):9280-90
19010901
Cancer Cell. 2004 Apr;5(4):317-28
15093539
Int J Oncol. 2000 Jan;16(1):65-73
10601550
Oncogene. 2005 Sep 15;24(41):6213-21
16091755
Mol Cancer Ther. 2009 Jan;8(1):185-93
19139128
J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25
11106683
Biochim Biophys Acta. 2006 Apr;1758(4):429-42
16678786
Br J Cancer. 2001 May 4;84(9):1252-7
11336478
Ann Surg Oncol. 2010 Jan;17(1):14-7
19841980
Mol Pharm. 2010 Apr 5;7(2):543-56
20047302
Cancer Res. 2003 Jun 15;63(12):3257-62
12810656
Ann Oncol. 2001;12 Suppl 1:S3-8
11521719
Surgery. 1999 Aug;126(2):413-21
10455915
Biochemistry. 2000 May 30;39(21):6572-80
10828974
Cancer. 1996 Jan 1;77(1):113-20
8630916
Int J Gynecol Cancer. 2007 Jul-Aug;17(4):798-807
17309668
J Natl Cancer Inst. 1986 Nov;77(5):1047-52
3464796
J Cell Biol. 2003 Jun 23;161(6):1191-203
12810698
J Surg Res. 1998 Jun;77(1):85-90
9698539
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S17-27
16113093
Mol Cell Biol. 2005 Dec;25(24):11005-18
16314522
BioDrugs. 2007;21(4):209-14
17628118
Cancer Cell. 2002 Aug;2(2):127-37
12204533
Mol Cancer Res. 2003 Mar;1(5):385-92
12651911
Nature. 2001 Mar 1;410(6824):24-5
11242022
Cancer. 2003 Oct 1;98(7):1377-85
14508823
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63
10318905
Breast Cancer Res. 2003;5(6):R217-22
14580257
J Med Chem. 2002 Sep 12;45(19):4336-43
12213074
J Clin Oncol. 2003 Jan 15;21(2):283-90
12525520
Cell Mol Life Sci. 2008 Nov;65(23):3756-88
18726070
Eur J Cancer. 2007 Feb;43(3):481-9
17208435
J Cell Biol. 2004 Nov 8;167(3):469-78
15534001
ChemMedChem. 2008 Dec;3(12):1839-43
19012296
Oncogene. 2002 Sep 12;21(41):6255-63
12214266
Cancer Res. 2009 Dec 15;69(24):9330-6
19934333
Oncogene. 1996 Sep 5;13(5):883-9
8806677
J Biomed Sci. 2003 May-Jun;10(3):337-44
12711861
Cancer Res. 2007 Apr 1;67(7):3337-44
17409443
Cancer Gene Ther. 2001 Aug;8(8):555-65
11571533
Cancer Res. 1995 Aug 1;55(15):3331-8
7614468
Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2
17139244
Nat Biotechnol. 2005 Jun;23(6):709-17
15908939
Mol Cancer Ther. 2007 Jan;6(1):93-100
17237269
Cancer Res. 2004 Apr 1;64(7):2343-6
15059883
Clin Cancer Res. 2002 Apr;8(4):955-6
11948099
Semin Oncol. 2001 Aug;28(4 Suppl 15):71-6
11685733
Mol Cancer Ther. 2005 Jun;4(6):956-67
15956253
Neoplasia. 2004 Nov-Dec;6(6):786-95
15720805
Cancer Res. 2007 Jan 1;67(1):269-75
17210707
Biophys J. 2009 Mar 18;96(6):2321-34
19289058
Nat Cell Biol. 2001 Sep;3(9):802-8
11533659
Prostate. 2004 Sep 1;60(4):332-7
15264245
Cancer Res. 2005 Apr 15;65(8):3404-9
15833875
Clin Cancer Res. 2004 Mar 1;10(5):1706-16
15014023
Nature. 2002 Mar 21;416(6878):279-80
11907566
Cancer Res. 1991 Feb 1;51(3):1034-8
1670998
FASEB J. 2003 Feb;17(2):256-8
12490548
Curr Hematol Rep. 2004 Jul;3(4):267-73
15217556
Nat Med. 1999 Mar;5(3):280-5
10086382
Cancer Res. 2005 Feb 1;65(3):967-71
15705897
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
J Natl Cancer Inst. 2000 Dec 6;92(23):1866-8
11106669
Oncogene. 1995 Jun 15;10(12):2435-46
7784095
Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64
14613027
Cancer Gene Ther. 2005 Jan;12(1):84-9
15472715
Eur J Cancer. 2000 Apr;36(6):780-6
10762752
J Biol Chem. 2002 Feb 15;277(7):4704-12
11741943
Expert Opin Biol Ther. 2010 Feb;10(2):243-50
20001562
Cancer. 1993 Dec 1;72(11):3179-84
7902202
Cancer Res. 2005 Mar 1;65(5):1783-91
15753375
Nature. 2001 Mar 1;410(6824):50-6
11242036
Cancer. 2003 Nov 15;98(10):2125-32
14601081
Cancer Res. 2000 Feb 1;60(3):560-5
10676637
Nat Biotechnol. 2000 Feb;18(2):194-8
10657127
Protein Eng Des Sel. 2004 May;17(5):455-62
15208403
Mol Endocrinol. 2001 Aug;15(8):1344-59
11463858
Cancer Res. 2005 Aug 1;65(15):6891-900
16061673
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
Mol Cell. 2003 Feb;11(2):495-505
12620236
Cancer Biother Radiopharm. 2005 Jun;20(3):239-48
15989469
Eur J Cancer. 2004 Jan;40(1):33-42
14687787
Histopathology. 2000 Dec;37(6):536-45
11122436
Cell Prolif. 2007 Aug;40(4):488-507
17635517
J Clin Oncol. 2009 Dec 10;27(35):6052-69
19901123
Clin Med Res. 2009 Jun;7(1-2):4-13
19574486
Clin Breast Cancer. 2008 Oct;8(5):392-401
18952552